Ixchelsis Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $8.05M
Latest Deal Amount
  • Investors
  • 2

Ixchelsis General Information

Description

Developer of oxytocin receptor antagonists designed to focus on male sexual health. The company's antagonists have achieved positive proof of concept and have the potential to treat premature ejaculation (PE), enabling healthcare professionals to get a therapeutic approach for the treatment of male reproductive health.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • Discovery Park House, Discovery Park
  • Ramsgate Road, Sandwich
  • Kent CT13 9NJ
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ixchelsis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 30-Oct-2017 $8.05M 0000 000.00 Completed Generating Revenue
3. Early Stage VC 05-Dec-2016 0000 000.00 Completed Generating Revenue
2. Early Stage VC 06-Aug-2014 $6.9M $20.9M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 06-Aug-2013 $14M $14M Completed Generating Revenue
To view Ixchelsis’s complete valuation and funding history, request access »

Ixchelsis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class C 0,000,000 00.000000 00.0 00.0 00 00.0 0.000
Class C 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Class C 0,000,000 00.000000 00.0 00.0 00 00.0 0.000
B Ordinary 6,878,838 $0.001319 $0.78 $0.78 1x $0.78 27.74%
B Ordinary 7,621,159 $0.001319 $1.33 $1.33 1x $1.33 30.73%
To view Ixchelsis’s complete cap table history, request access »

Ixchelsis Executive Team (4)

Name Title Board Seat Contact Info
Gary Muirhead Co-Founder, Board Member and Chief Executive Officer
Lizbeth Littlewood Chief Operating Officer & Secretary
Ian Osterloh Chief Medical Officer
Karl Gibson Ph.D Co-Founder & Chief Technology Officer
To view Ixchelsis’s complete executive team members history, request access »

Ixchelsis Board Members (3)

Name Representing Role Since
Barbara Dalton Ph.D Pfizer Ventures Board Member 000 0000
Gary Muirhead Ixchelsis Co-Founder, Board Member and Chief Executive Officer 000 0000
Luc Marengère Ph.D TVM Capital Life Science Board Member 000 0000
To view Ixchelsis’s complete board members history, request access »

Ixchelsis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ixchelsis Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Pfizer Ventures Corporate Venture Capital Minority 000 0000 000000 0
TVM Capital Life Science Venture Capital Minority 000 0000 000000 0
To view Ixchelsis’s complete investors history, request access »